STOCKHOLM -- An investigational antiplatelet -- ticagrelor (Brilinta) -- emerged as a big winner from the five-day long European Society of Cardiology congress, but the buzz here focused instead on a trio of investigational oral anticoagulants -- dabigatran, rivaroxaban, and apixaban.
